Bosutinib in (Ph+) Chronic Myelogenous LeukemiaBosutinib in (Ph+) Chronic Myelogenous Leukemia
Owing to its favorable toxicity profile and its high antileukemic activity, bosutinib is a promising novel treatment option for patients with CML. Therapeutic Advances in Hematology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
More News: Cancer & Oncology | Chronic Leukemia | Chronic Myeloid Leukaemia | Health | Hematology | Leukemia | Toxicology